A policy shift would move the U.S. FDA from a punitive first-in-human fee structure toward a reward-based approach under reauthorized PDUFA. The change would reduce certain fees for domestic first-in-human (FIH) trials, rather than imposing a penalty tied to overseas trial activity. The development signals an operational change that can affect how sponsors structure early clinical programs, including country selection, site planning, and incremental trial readiness. For developers, it also raises the value of domestic FIH execution as a cost lever rather than simply a logistical choice. Industry watchers will likely track how the fee adjustments interact with broader FDA oversight priorities and how companies adapt their global clinical strategy.